CU23273B7 - MUTEINAS SELECTIVAS PARA LA ACTIVACION DE CéLULAS T Y COMPOSICIONES CONTENIENDO DICHAS MUTEINAS - Google Patents

MUTEINAS SELECTIVAS PARA LA ACTIVACION DE CéLULAS T Y COMPOSICIONES CONTENIENDO DICHAS MUTEINAS

Info

Publication number
CU23273B7
CU23273B7 CU20000257A CU20000257A CU23273B7 CU 23273 B7 CU23273 B7 CU 23273B7 CU 20000257 A CU20000257 A CU 20000257A CU 20000257 A CU20000257 A CU 20000257A CU 23273 B7 CU23273 B7 CU 23273B7
Authority
CU
Cuba
Prior art keywords
cells
muteins
compositions containing
muteines
selective
Prior art date
Application number
CU20000257A
Other languages
English (en)
Inventor
Gayle D Wetzel
Kenneth J Lembach
Gary Jesmok
Jeffrey M Greve
Armen B Shanafelt
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CU23273B7 publication Critical patent/CU23273B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La invencion se dirige a un polipÉptido que consiste en una muteína de IL-2 humana numerada de acuerdo con IL-2 tipo silvestre, en donde la IL-2 humana es sustituida en cuando menos una de las posiciones 20, 88 o 126, mediante lo cual la muteína activa preferencialmente cÉlulas T sobre cÉlulas NK. D2OH y I, N88G, I, y R en particular tienen una actividad diferencial de cÉlulas T relativa mucho mayor que IL-2 nativa, con toxicidad reducida in vivo asociada, pronosticada. La invencion tambiÉn incluye polinucleotidos que codifican para las muteínas de la invencion, vectores que contienen los polinucleotidos, cÉlulas hospederas transformadas, composiciones farmacÉuticas que contienen las muteínas y los mÉtodos terapÉuticos de tratamiento.
CU20000257A 1998-05-15 2000-11-15 MUTEINAS SELECTIVAS PARA LA ACTIVACION DE CéLULAS T Y COMPOSICIONES CONTENIENDO DICHAS MUTEINAS CU23273B7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
CU23273B7 true CU23273B7 (es) 2008-04-09

Family

ID=22155135

Family Applications (2)

Application Number Title Priority Date Filing Date
CU20000257A CU23273B7 (es) 1998-05-15 2000-11-15 MUTEINAS SELECTIVAS PARA LA ACTIVACION DE CéLULAS T Y COMPOSICIONES CONTENIENDO DICHAS MUTEINAS
CU20020125A CU23272A1 (es) 1998-05-15 2002-06-19 MéTODO DE TRATAMIENTO EN MAMIFEROS CON DESORDENES CELULARES UTILIZANDO UNA MUTEINA IL-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
CU20020125A CU23272A1 (es) 1998-05-15 2002-06-19 MéTODO DE TRATAMIENTO EN MAMIFEROS CON DESORDENES CELULARES UTILIZANDO UNA MUTEINA IL-2

Country Status (39)

Country Link
EP (1) EP1076704B1 (es)
JP (1) JP4276783B2 (es)
KR (1) KR100607609B1 (es)
CN (2) CN100366742C (es)
AR (1) AR020322A1 (es)
AT (1) ATE351907T1 (es)
AU (1) AU759697B2 (es)
BG (1) BG65139B1 (es)
BR (1) BRPI9910504B1 (es)
CA (1) CA2327349C (es)
CO (1) CO5070701A1 (es)
CU (2) CU23273B7 (es)
CY (1) CY1107533T1 (es)
CZ (1) CZ302071B6 (es)
DE (1) DE69934881T2 (es)
DK (1) DK1076704T3 (es)
DZ (1) DZ2788A1 (es)
ES (1) ES2281175T3 (es)
HK (1) HK1039963B (es)
HN (1) HN1999000075A (es)
HU (1) HU226142B1 (es)
IL (2) IL139136A0 (es)
MY (1) MY130274A (es)
NO (1) NO329235B1 (es)
NZ (1) NZ508098A (es)
PA (1) PA8472601A1 (es)
PE (1) PE20000475A1 (es)
PL (1) PL201675B1 (es)
PT (1) PT1076704E (es)
RO (1) RO122150B1 (es)
RU (1) RU2235729C2 (es)
SI (1) SI20643B (es)
SK (1) SK288100B6 (es)
SV (1) SV1999000061A (es)
TN (1) TNSN99090A1 (es)
TR (1) TR200003354T2 (es)
TW (1) TWI223663B (es)
UA (1) UA73719C2 (es)
WO (1) WO1999060128A1 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
WO2000058456A2 (en) * 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
RU2272644C2 (ru) 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
JP4494977B2 (ja) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
SG148143A1 (en) 2003-11-04 2008-12-31 Novartis Vaccines & Diagnostic Antagonist anti-cd40 monoclonal antibodies and methods for their use
JP5744369B2 (ja) * 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CN101244261B (zh) * 2008-03-10 2010-09-15 山东大学 一种含未复性重组蛋白的生物制剂及其制备方法与应用
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
AU2010206840B2 (en) 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
HRP20210642T1 (hr) 2010-11-12 2021-05-28 Nektar Therapeutics Konjugati il-2 ostatka i polimera
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
US9266938B2 (en) 2011-02-10 2016-02-23 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
CN111423513A (zh) 2014-02-06 2020-07-17 豪夫迈·罗氏有限公司 白介素-2融合蛋白和其用途
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
SG11201700629TA (en) 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7407511B2 (ja) 2015-10-08 2024-01-04 ネクター セラピューティクス ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109071623B (zh) * 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
EP3458485B1 (en) * 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
IL263874B2 (en) * 2016-06-22 2025-02-01 David Klatzmann Genetically modified T lymphocytes
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
CN110177564A (zh) * 2016-12-13 2019-08-27 德里尼亚公司 多价的调节t细胞调节剂
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN111107868A (zh) * 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag IL2 antibody grafted proteins and methods of use in cancer treatment
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
MA49767A (fr) * 2017-08-03 2021-05-26 Synthorx Inc Conjugués de cytokine pour le traitement de maladies auto-immunes
US20200299349A1 (en) * 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3728302A1 (en) 2017-12-19 2020-10-28 Xencor, Inc. Engineered il-2 fc fusion proteins
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
BR112020019639A2 (pt) 2018-03-28 2021-01-05 Ascendis Pharma Oncology Division A/S Conjugados de il-2
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
JP7550745B2 (ja) * 2018-07-24 2024-09-13 バイオエヌテック エスエー Ｉｌ２アゴニスト
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CA3086486A1 (en) 2018-09-17 2020-03-26 Gi Innovation, Inc. Fusion protein comprising il-2 protein and cd80 protein, and use thereof
AU2019344875B2 (en) 2018-09-21 2021-12-23 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin 2 and use thereof
TWI791894B (zh) 2018-09-21 2023-02-11 大陸商信達生物製藥（蘇州）有限公司 新型白介素２及其用途
EP3875475A4 (en) 2018-12-21 2022-12-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. VARIANT OF HUMAN INTERLEUKIN-2 OR ITS DERIVATIVE
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
MX2022001866A (es) * 2019-08-13 2022-03-11 Amgen Inc Muteinas de interleucina-2 para la expansion de celulas t reguladoras.
BR112022011414A2 (pt) 2019-12-12 2022-08-30 Iltoo Pharma Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
MX2022008770A (es) * 2020-01-14 2022-10-07 Synthekine Inc Muteinas de la il2.
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
AU2021239225B2 (en) 2020-03-19 2024-08-15 Fortvita Biologics (Singapore) Pte.Ltd. Interleukin-2 mutant and use thereof
MX2022011893A (es) 2020-03-31 2022-10-18 Hanmi Pharm Ind Co Ltd Nuevos analogos de il-2 inmunoestimuladores.
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
IL302114A (en) 2020-10-29 2023-06-01 Bristol Myers Squibb Co Fusion proteins for the treatment of disease
MX2023006599A (es) 2020-12-04 2023-06-19 Visterra Inc Metodos de uso de agentes de interleucina-2.
CN113308477A (zh) * 2021-04-08 2021-08-27 华南农业大学 一种鸭il-2基因真核表达重组质粒及其制备方法
CN118119635A (zh) 2021-09-22 2024-05-31 信达生物制药(苏州)有限公司 白介素2突变体以及其融合蛋白
KR20240113459A (ko) 2021-10-06 2024-07-22 일투 파마 염증 조직에 대한 표적화 특이성을 갖는 인터루킨 2 키메라 구성체
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
IL317511A (en) * 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
CA3265946A1 (en) 2022-09-12 2024-03-21 Sorbonne Universite INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS
FR3140287B1 (fr) 2022-10-03 2025-11-21 Arkema France Procede de granulation de composes azoiques et granules obtenus
EP4631972A1 (en) 2022-11-18 2025-10-15 Nanjing Novoacine Biotechnology Co., Ltd. Site-specific coupled pegylated interleukin-2 mutant with receptor affinity preference and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003334C1 (ru) * 1988-07-26 1993-11-30 Хем Рисерч, Инк, (US) Способ лечени больных с опухол ми
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
CN100366742C (zh) 2008-02-06
ES2281175T3 (es) 2007-09-16
JP2002515247A (ja) 2002-05-28
EP1076704A1 (en) 2001-02-21
CZ302071B6 (cs) 2010-09-29
DE69934881D1 (de) 2007-03-08
AR020322A1 (es) 2002-05-08
AU759697B2 (en) 2003-04-17
HUP0101948A2 (hu) 2001-09-28
CN101319247A (zh) 2008-12-10
HN1999000075A (es) 1999-09-29
PA8472601A1 (es) 2000-09-29
CO5070701A1 (es) 2001-08-28
JP4276783B2 (ja) 2009-06-10
DE69934881T2 (de) 2007-11-08
NO329235B1 (no) 2010-09-20
NO20005762L (no) 2001-01-11
ATE351907T1 (de) 2007-02-15
EP1076704B1 (en) 2007-01-17
CA2327349A1 (en) 1999-11-25
IL139136A0 (en) 2001-11-25
SV1999000061A (es) 2000-03-14
HK1039963A1 (zh) 2002-05-17
CN101319247B (zh) 2012-12-12
PE20000475A1 (es) 2000-07-07
BG65139B1 (bg) 2007-03-30
BRPI9910504B1 (pt) 2016-08-09
CY1107533T1 (el) 2013-03-13
CZ20004213A3 (en) 2001-05-16
BR9910504A (pt) 2001-01-09
MY130274A (en) 2007-06-29
PL201675B1 (pl) 2009-04-30
CA2327349C (en) 2010-10-26
KR20010043602A (ko) 2001-05-25
CN1309705A (zh) 2001-08-22
BG104929A (en) 2001-09-28
DK1076704T3 (da) 2007-03-12
CU23272A1 (es) 2008-04-09
TNSN99090A1 (fr) 2005-11-10
NO20005762D0 (no) 2000-11-14
KR100607609B1 (ko) 2006-08-02
PT1076704E (pt) 2007-02-28
DZ2788A1 (fr) 2003-12-01
SI20643A (sl) 2002-02-28
HU226142B1 (en) 2008-05-28
TR200003354T2 (tr) 2001-03-21
SI20643B (sl) 2008-02-29
SK288100B6 (sk) 2013-07-02
HK1039963B (zh) 2008-09-05
IL139136A (en) 2009-05-04
PL344407A1 (en) 2001-11-05
HUP0101948A3 (en) 2003-08-28
RO122150B1 (ro) 2009-01-30
SK17242000A3 (sk) 2001-07-10
TWI223663B (en) 2004-11-11
UA73719C2 (en) 2005-09-15
RU2235729C2 (ru) 2004-09-10
WO1999060128A1 (en) 1999-11-25
NZ508098A (en) 2003-09-26
AU4078499A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
CU23273B7 (es) MUTEINAS SELECTIVAS PARA LA ACTIVACION DE CéLULAS T Y COMPOSICIONES CONTENIENDO DICHAS MUTEINAS
EA200500120A1 (ru) Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
LTPA2017030I1 (lt) Interferono beta-1A polimero konjugatai ir jų panaudojimas
KR910003102A (ko) 사람 에리트로포이에틴의 뮤테인
DK0851925T3 (da) Humane Væksthormonvarianter
ATE358176T1 (de) Menschliche dnase
DE69832375D1 (de) Verwendungsmethoden von makrozyklischen laktonen als mittel zur umkehrung der mehrfach-medikamentresistenz in krebs- und anderen zellen
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
ES2053763T3 (es) Composiciones estabilizadas de isotiazolonas.
ES2117724T3 (es) Dispositivo de cobertura para cavidad osea.
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ES2119912T3 (es) Nuevos aminometilenpeptidos como inmunosupresores.
SE8102194L (sv) Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
SE8702642L (sv) Lokalt anvendbara, farmaceutiska beredningar
BR9812316A (pt) Formulações de camptotecina lipossÈmica
MX9203320A (es) Composicion antialergica que contiene compuestos biciclicos switterionicos.
ES2094907T3 (es) Secuencias de adn que codifican para caracteristicas de virulencia de -s(streptococcus suis) y partes del mismo, polipeptidos y anticuerpos derivados de este y su uso para la diagnosis y la proteccion contra la infeccion por -s(s. suis) en mamiferos, incluyendo el ser humano.
ES2103854T3 (es) Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
BR0206852A (pt) Conjugados de polìmero de neublastina e métodos para uso dos mesmos
ES2052654T3 (es) Preparacion polimera endurecible por agua.
ES2154002T3 (es) 2-naftoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
NO913129D0 (no) Nytt trombolytisk middel.
ES2039040T3 (es) Paramentos para movimientos de tierra.
ECSP992953A (es) Agonistas y antagonistas il-2 selectivos (caso 5038p1-ec)

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)